caa a22 4500 606158030 CHVBK 20210128100617.0 cr unu---uuuuu 210128e20151101xx s 000 0 eng 10.1007/s10096-015-2473-z doi (NATIONALLICENCE)springer-10.1007/s10096-015-2473-z Rapid detection of carbapenemase activity: benefits and weaknesses of MALDI-TOF MS [Elektronische Daten] [C. Mirande, I. Canard, S. Buffet Croix Blanche, J.-P. Charrier, A. van Belkum, M. Welker, S. Chatellier] Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) has been introduced as an identification procedure for bacteria and fungi. The MALDI-TOF MS-based analysis of resistance to β-lactam antibiotics has been applied to detect hydrolysis of carbapenems by different bacterial strains. However, the detection of enzymatic carbapenem degradation by MALDI-TOF MS lacks well-standardized protocols and several methods and models of interpretation using different calculations of ratio-of-peak intensities have been described in the literature. Here, we used faropenem and ertapenem hydrolysis as model compounds. In an attempt to propose a universal protocol, the hydrolysis was regularly monitored during 24h using well-characterized bacterial strains producing different types of carbapenemases (KPC, IMP, NDM, VIM, and OXA-48). Variable responses and different timing for detectable hydrolysis, depending on the enzyme produced, were observed. KPC degrades its template antibiotics very quickly (15min for some KPC producers) compared to other types of enzymes (more than 90min for other enzymes). Prior bacterial lysis was shown to be of no interest in the modulation or optimization of the hydrolytic kinetics. The adequate detection of carbapenem hydrolysis would, therefore, require several MALDI-TOF MS readouts for the timely detection of rapid hydrolysis without missing slow hydrolysis. This enzymatic constraint limits the implementation of a standard protocol in routine microbiology laboratories. Springer-Verlag Berlin Heidelberg, 2015 Mirande C. Microbiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France aut Canard I. Microbiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France aut Buffet Croix Blanche S. Microbiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France aut Charrier J.-P TRD—Innovation Unit, bioMérieux SA, Marcy L'Étoile, France aut van Belkum A. R&D Microbiology, bioMérieux SA, La Balme-les-Grottes, France aut Welker M. R&D Microbiology, bioMérieux SA, La Balme-les-Grottes, France aut Chatellier S. Microbiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France aut European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/11(2015-11-01), 2225-2234 0934-9723 34:11<2225 2015 34 10096 https://doi.org/10.1007/s10096-015-2473-z text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10096-015-2473-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mirande C. Microbiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France aut NATIONALLICENCE 700 1- Canard I. Microbiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France aut NATIONALLICENCE 700 1- Buffet Croix Blanche S. Microbiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France aut NATIONALLICENCE 700 1- Charrier J.-P TRD—Innovation Unit, bioMérieux SA, Marcy L'Étoile, France aut NATIONALLICENCE 700 1- van Belkum A. R&D Microbiology, bioMérieux SA, La Balme-les-Grottes, France aut NATIONALLICENCE 700 1- Welker M. R&D Microbiology, bioMérieux SA, La Balme-les-Grottes, France aut NATIONALLICENCE 700 1- Chatellier S. Microbiology Innovation Unit, bioMérieux SA, 3 route de Port Michaud, La Balme-les-Grottes, France aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/11(2015-11-01), 2225-2234 0934-9723 34:11<2225 2015 34 10096